Male and female cigarette smokers ( n = 30) and nonsmokers ( n = 30) were recruited from the Baltimore, M aryland area. Smokers averaged (mean ± SD ) 21 ± 6 cigarettes/day, had smoked for 15.8 ± 10.2 years, were moderately nicotine dependent ( Fagerström Test for Nicotine Dependence = 5.2 ± 1.6) and were 30.8 ± 9.2 years old. Nonsmokers reported smoking less than 10 cigarettes ever and were 29.8 ± 8.5 years old. Smokers
In contrast, the effect of nicotine is less clear on executive attention, which involves detecting and resolving confl ict . Nicotine gum had no effect on executive attention in nonsmokers , whereas AhnAllen, Nestor, reported that transdermal nicotine improved executive attention in smokers.
To clarify the effect of nicotine on executive attention, we administered intranasal nicotine (0, 0.5, 1.5 mg) to smokers and nonsmokers and assessed measures of executive and alerting attention. We also assessed subjective and cardiovascular effects of nicotine. We hypothesized that nicotine would ( a ) dosedependently enhance executive and alerting attention similarly in smokers and nonsmokers and ( b ) elicit greater subjective and cardiovascular effects in nonsmokers than smokers because of chronic nicotine tolerance in smokers.
Introduction
A major impediment to quitting smoking is the nicotine withdrawal syndrome, which includes difficulty concentrating ( American Psychiatric Association, 2000 ) . The reversal of abstinence-induced cognitive defi cits by smoking or nicotine has been documented . Additionally, nicotine enhances some elements Nicotine enhances attention 2 Nicotine enhances attention and nonsmokers did not differ signifi cantly in age, education, and estimated IQ. All participants provided written informed consent and were paid for their participation. The National Institute on Drug Abuse (NIDA) Institutional Review Board approved the study.
Procedures
Participants completed one adaptation and three experimental sessions. They were required to abstain from alcohol and other drugs (except caffeine, nicotine, and prescription drugs) 24 hr before each session. Smokers smoked ad libitum before sessions and smoked one preferred-brand cigarette 60 min before each session. During the adaptation session, participants practiced the attention tests and were familiarized with the subjective rating scales. At the end of the session, smokers were administered the highest nicotine dose (1.5 mg) to screen for adverse effects. Nonsmokers received 0.5 mg nicotine, and if tolerated, received 1.5 mg 30 min later. Five nonsmokers could not tolerate the nicotine doses and were discharged from the study.
Experimental sessions lasted 2 hr and were conducted at least 24 hr apart. At each session, a single dose of nicotine (0, 0.5, or 1.5 mg) was administered in randomized order. Participants performed a 30-min battery of attention, subjective, and cardiovascular measures before and after each dose. Nicotine was administered in the form of the marketed nasal spray Nicotrol® (Pfi zer) and a placebo spray was formulated by the NIDA pharmacy, as described previously . The placebo solution was placed in empty Nicotrol bottles to allow double-blind administration.
Attention Measures
Executive attention was measured using a Rapid Serial Visual Presentation (RSVP) task and the Attention Network Test (ANT). The RSVP task can assess the attentional blink phenomenon in which two target words (T1 and T2) are presented with a varying number of intervening distracter words (lags). Participants are typically accurate at reporting T1; however when T2 follows T1 within 500 ms (early lags), identifi cation of T2 is impaired, as if our attentional system " blinked " . The RSVP task used in this study has been described . Briefl y, participants completed 48 trials, each of which contained 16 individually presented words (T1, T2, and 14 distracters). Target words were selected from a list of commonly used nouns whereas the 14 distracter words were less commonly used nouns. Across sessions, no word was presented more than once; all words were unrelated to smoking and emotionally neutral. The task lasted 10 -15 min. Correct reporting of T1 measured alerting attention; identifi cation of T2, especially at early T1 -T2 lags, assessed executive attention. The ANT is a combination of a cued reaction time task and a fl anker task . Participants completed 2 blocks of 96 trials. For each trial, the target was an arrow presented above or below a fi xation cross on the monitor. Participants indicated whether the arrow was pointing left or right. The central arrow was fl anked on either side by two arrows pointing in the same direction (congruent cue), the opposite direction (incongruent cue), or by straight lines. Subtraction of response times to congruent cues from incongruent cues yielded a measure of executive attention. Alerting attention was assessed by two warning conditions that cued the onset of the target arrow: fi xation cross only (no cue) or an asterisk above and below the fi xation cross (double cue). Subtraction of response time to double cue from no cue yielded a measure of alerting attention .
Alerting attention was also measured using a 6-min CPT . Participants viewed letters displayed on a monitor one at a time in rapid succession (100 ms presentation, 600 ms interstimulus interval) and pressed a button when they saw the letter " X . " There were 100 targets and 400 nontargets presented each session. To make the task more challenging, we used a degraded version in which 30% of the pixels of each letter were absent. Dependent variables were correct target responses, errors of commission, adjusted target responses (target responses minus errors of commission), mean response time, and response time variability.
Subjective and Cardiovascular Measures
The Positive and Negative Affect Schedule (PANAS) is a validated scale measuring positive and negative mood . Individual items were averaged for a composite positive and negative mood score. PANAS items were measured 20-min postdose to evaluate participants ' mood near the end of each session. The following Visual Analog Scale (VAS) items were assessed: stimulated, jittery, dizzy, drug liking, drug strength, good drug effect, bad drug effect, and urge to smoke. Participants answered each item by placing a vertical mark along a 100-mm line anchored by not at all on the left and extremely on the right. VAS items were measured 5-min postdose to evaluate acute nicotine effects. Heart rate and blood pressure were measured 30 min before and 5 min after each nicotine dose.
Data Analysis
We assessed baseline performance on the participants ' fi rst experimental session before drug was delivered. Because there was a signifi cant group difference on CPT baseline performance (nonsmokers made more errors of commission than smokers, p < .05), we used this baseline session as a covariate on subsequent analyses of the CPT. There were two independent variables, group (smokers and nonsmokers) and nicotine dose (0, 0.5, 1.5 mg). The independent variables for the ANT, subjective, and cardiovascular data were group, dose, and trial (predrug vs . postdrug); the RSVP task had a fourth independent variable, T1 -T2 lag positions. Because of missing data on some tasks, analyses were conducted using the Mixed Models procedure in SPSS, which allows for missing data without resorting to imputation. Analysis of RSVP data was conducted using GLM repeated measures in SPSS. Statistical tests were two tailed with alpha = .05. Post -hoc comparisons between means were conducted using the protected Fisher ' s least signifi cant difference test . This procedure was deliberately chosen to avoid the Type II error by minimizing alpha correction.
Results
At baseline, nonsmokers made a higher percentage of errors of commission compared with smokers, t = 2.21, p < .05; 60.04 Post-hoc tests showed that nonsmokers ' performance was signifi cantly improved following the highest dose of nicotine compared with 0.5 mg, p < .05 and placebo, p < .05. Smokers showed a similar pattern but did not reach signifi cance. Figure 1 shows that nicotine reduced errors of commission without concomitant reductions in target responses.
On the RSVP, there was a signifi cant group × trial × dose interaction for T1 reporting, F (2, 112) = 4.53, p < .05. Smokers ' T1 identifi cation improved following 0.5 mg nicotine as compared with the predrug condition, ( p < .05). Identifi cation of T2 was poorer at early lags than later lags, F (7, 392) = 119.5, p < .001, refl ecting the attentional blink effect; however, there were no signifi cant nicotine effects on T2 reporting ( Table 1 ) . There were no signifi cant effects of nicotine on the ANT ( Table 1 ) .
On most subjective measures, the effect of nicotine differed between smokers and nonsmokers ( Table 2 ). There were significant drug effects on all VAS items except urge to smoke. For example, following nicotine, participants felt more stimulated (trial × dose, F (2, 290) = 3.16, p < .05), more jittery (trial main effect, F (1, 290) = 10.87, p = .001) and dizzier (dose main effect, F (2, 290) = 7.6, p = .001). Post-hoc tests showed these effects were observed primarily in nonsmokers, although the highest dose also produced increased dizziness in smokers. Post-hoc tests showed that liking scores were signifi cantly increased by nicotine in nonsmokers ( p < .05) and nearly so in smokers ( p = .051). Nicotine had no effect on the PANAS.
At 5-min postdose, nicotine increased blood pressure in smokers ( p < .05) and nonsmokers ( p < .05) and produced a dose-related increase in heart rate ( p < .01). There were no differences between smokers and nonsmokers. Note. a Data are subtractions of response times, as a measure of the effi ciency of attention processing ) . * p < .05. predrug versus postdrug.
Discussion
The purpose of this study was to clarify the effect of nicotine in smokers and nonsmokers on executive attention, which involves detecting and resolving conflict among stimuli . We assessed executive attention in two tasks. In the RSVP task, attending to one target word interferes with the identifi cation of a second word, and in the ANT, incongruent fl anking arrows confl ict with identifying the direction of the central arrow. Nicotine had no effect on the confl icting elements of either task in smokers and nonsmokers.
To our knowledge, this is the fi rst study to investigate the effect of nicotine on the attentional blink phenomenon, a form of executive attention. Nicotine had no effect on T2 word identifi cation at early T1 -T2 lags when the competition for resources is greatest. We previously found impaired identifi cation of T1 words in smokers after overnight tobacco deprivation when words were presented for 113 ms, but deprivation also had no effect on the attentional blink . Consistent with our negative fi ndings, reported no effect of nicotine gum on ANT executive attention in nonsmokers. AhnAllen et al. (2008) reported improved performance in smokers following transdermal nicotine, but because subjects were tobacco deprived overnight, the improvement was likely due to withdrawal relief. Executive attention in the ANT also was not sensitive to the nicotinic antagonist, mecamylamine ).
Nicotine enhances attention

In contrast to the lack of effect on executive attention, nicotineenhanced alerting attention by decreasing errors of commission on the CPT in nonsmokers and improving the correct identification of T1 target words on the RSVP task in smokers. There was no nicotine effect on alerting as measured by the ANT, which might be a function of the tasks measuring alerting in different ways -that is, the ANT is a cued reaction time task. The differential responses to nicotine between smokers and nonsmokers on these tasks is not unusual in the literature and might reflect a combination of Drug strength 0 mg 1.0 (4.5) 27.5 (4.5)** 8.8 (4.5) 24.67 (4.5)** 0.5 mg 1.5 (4.5) 27.0 (4.5)** 8.13 (4.5) 32.1 (4.5)** 1.5 mg 1.3 (4.5) 37.13 (4.5)** 9.8 (4.5) 34.1 (4.5)** Good drug effect 0 mg 1.1 (3.8) 16.0 (3.8)** 7.7 (3.8) 21.1 (3.8)** 0.5 mg 1.9 (3.8) 21.8 (3.8)** 9.7 (3.8) 19.9 (3.8)* 1.5 mg 6.2 (3.8) 21.1 (3.8)** 7.7 (3.8) 22.9 (3.8)** Bad drug effect 0 mg 0.9 (4.7) 21.0 (4.7)** 12.1 (4.7) 24.3 (4.7)* 0.5 mg 1.9 (4.7) 28.1 (4.7)** 11.1 (4.7) 32.2 (4.7)** 1.5 mg 2.7 (4.7) 32.6 (4.7)** 10.9 (4.7) 23. Note. + p = .051 . * p < .05 . ** p < .001 .
chronic nicotine exposure and preexisting trait differences ).
We hypothesized that nonsmokers would show greater subjective and cardiovascular effects of nicotine because of nicotine tolerance in smokers . Nonsmokers were indeed more sensitive to negative effects such as jittery and dizzy; but they, as did smokers, rated all doses of nicotine as having a good drug effect. Both groups were similarly sensitive to the cardiovascular effects of nicotine.
In summary, the acute administration of intranasal nicotine improved alerting attention in nonsmokers as measured by the CPT, and in smokers as measured by the RSVP. Nicotine had no effect on executive attention as measured by the RSVP and the ANT. Empirical data on the elements of attention enhanced by nicotine might guide the development of novel medications for the treatment of tobacco dependence. Additionally, in a recent meta-analysis , signifi cant positive effect sizes of nicotine on cognitive performance were observed in both nonsmokers and smokers, with no difference between the two groups. The authors concluded that the results in nonsmokers is indirect evidence that cognitive enhancement might be one reason people decide to start smoking. However, whether or not the cognitive enhancing effects of nicotine reinforce cigarette smoking remains to be answered.
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